Johnson & Johnson (NYSE:JNJ) has submitted a supplemental Biologics License Application for its drug Darzalex Faspro in ...
The application is for the treatment, called darzalex faspro, to be used in combination with an existing multiple myeloma treatment -- called bortezomib, lenalidomide and dexamethasone -- for adult ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...
2d
Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...
Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...
3d
Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...
Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.
By: Milan Sheth, M.D., hematology/oncology, MemorialCare Todd Cancer Institute at Long Beach Medical Center MemorialCare is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback